Search clinical trials for: BIIB041 (Fampridine-PR)

Total 513 results

Biogen
Acorda Therapeutics

Completed

Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

Multiple Sclerosis

Canada
Biogen

Completed

Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. (MOBILE)

Multiple Sclerosis

Sweden, United Kingdom, Netherlands, Belgium, Canada, Italy
Biogen
Acorda Therapeutics

Completed

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers

Healthy

Hong Kong, Australia
Biogen

Completed

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (MOTION - JAPAN)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent Progressive

Japan
Biogen

Terminated

Fampridine Pregnancy Exposure Registry

Multiple Sclerosis | Pregnancy

France
Biogen

Completed

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (ENABLE)

Multiple Sclerosis

France, Italy, United Kingdom, Germany, Australia, Belgium, Netherlands, Portugal, Denmark
Biogen

Completed

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis (ENHANCE)

Multiple Sclerosis

United States, Finland, Italy, United Kingdom, Bulgaria, Serbia, Russian Federation, Lithuania, Poland, Czech Republic, Netherlands
Biogen

Completed

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice (LIBERATE)

Multiple Sclerosis

France, Spain, Germany, Netherlands, Argentina, Czechia, Israel, Portugal, United Arab Emirates, Canada, Norway, Lebanon, Ireland
Biogen

Completed

Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors

Advanced Solid Tumors

United States
Biogen

Completed

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect

Healthy

United States
Biogen

Completed

Single-Dose Study of a New Formulation of BIIB061

Multiple Sclerosis

United States
University of Alberta
McGill University; Université de Sherbrooke; University of Toronto

Completed

The CaNadian Standardized Pulmonary Rehabilitation Efficacy Trial (CoNSPiRE)

Chronic Obstructive Pulmonary Disease (COPD)

Canada
Fondazione Salvatore Maugeri

Completed

Osteopathy in Chronic Obstructive Pulmonary Disease (COPD) Rehabilitation Trial

Chronic Obstructive Pulmonary Disease

Italy
Vedic Lifesciences Pvt. Ltd.

Completed

Cross-Over Study to Evaluate the Efficacy of E-PR-01 on Activity Induced Joint Pain

Joint Pain

India
Biogen

Not yet recruiting

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants (Mass Balance)

Healthy Volunteer
Biogen

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers

Healthy

United States
University of Glasgow
NHS Research and Development

Completed

An Evaluation of Web Based Pulmonary Rehabilitation (webbasedPR)

Chronic Obstructive Pulmonary Disease

United Kingdom
Biogen

Completed

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Aveiro University
Fundação para a Ciência e a Tecnologia

Completed

Impact of Family-based Pulmonary Rehabilitation (PR) on Patients With Chronic Obstructive Pulmonary Disease (COPD) and Their Family Members

Chronic Obstructive Pulmonary Disease (COPD)

Portugal
Biogen

Recruiting

A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis (FUSION)

Relapsing Forms of Multiple Sclerosis

Spain, United States, Italy, Switzerland, Germany, Bulgaria, Czechia, Poland, Puerto Rico, Romania
Biogen

Completed

New Formulation and Food Effect Study of BIIB074

Trigeminal Neuralgia (TN) | Other Neuropathic Pain

United States
Vedic Lifesciences Pvt. Ltd.

Completed

A Study to Evaluate the Efficacy of E-PR-01 on Musculoskeletal Health in Physically Active Individuals

Joint Pain

India
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Germany, Canada, Japan, Finland, Switzerland, Netherlands, Sweden
Biogen

Completed

A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants

Healthy Volunteers

United States
McMaster University

Recruiting

Impact of Pulmonary Rehabilitation on Loneliness in COPD

Loneliness

Canada
University of British Columbia

Completed

Sprint Snacks: The Effects of Prolonged Rest on Reduced Exertion Interval Training.

Cardiorespiratory Fitness

Canada
University Hospital, Brest

Recruiting

Impact on Quality of Life With Pulmonary RehAbilitation After Pulmonary eMBOlism: RAMBO Study (RAMBO)

Pulmonary Embolism | Quality of Life and Dyspnea

France
London School of Hygiene and Tropical Medicine
Wellcome Trust

Completed

Experimental Study to Assess Interventions Aimed at Improving the Equity Impact of Community-Based Health Insurance

Health Insurance

India
Biogen

Completed

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

Breast Cancer

United States
Aveiro University
Fundação para a Ciência e a Tecnologia

Completed

Home-monitoring and Adherence of Patients With COPD to Long-term Rehabilitation

Chronic Obstructive Pulmonary Disease (COPD)

Portugal
Biogen

Terminated

Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

B-Cell Chronic Lymphocytic Leukemia

United States
Biogen

Terminated

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States, Canada, United Kingdom, Netherlands, Switzerland
Biogen

Completed

Administration of BIIB028 to Subjects With Solid Tumors

Advanced Solid Tumors

United States
Grünenthal GmbH

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GRT9906 Prolonged Release Tablets After Dose Escalation in Healthy Subjects

Pharmacokinetics

Germany
Chang Gung Memorial Hospital

Unknown

Osteoporosis in Chronic Obstructive Pulmonary Disease (COPD)

Osteoporosis | COPD,

Taiwan
University of Nebraska
National Cancer Institute (NCI); Amgen

Completed

Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma

United States
Biogen

Completed

Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers

Healthy Volunteers

Australia, China
Columbia University
National Center for Complementary and Integrative Health (NCCIH)

Completed

Capnography-Assisted Learned Monitored (CALM) Breathing Therapy for COPD (CALM)

COPD

United States
Sociedad Española de Neumología y Cirugía Torácica

Completed

Cost/Effectiveness Analysis of the Respiratory Poligraphy at Home (Telesleep)

Suspected Sleep Apnea | Daytime Sleepiness

Spain
Biogen

Active, not recruiting

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Alzheimer's Disease

Korea, Republic of, United States, Spain, Belgium, Italy, Australia, Canada, Switzerland, Portugal, Taiwan, France, Poland, Germany, Netherlands, Sweden, Austria, Denmark, Japan, United Kingdom, Finland
Biogen

Withdrawn

802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia (SURGE-2)

Trigeminal Neuralgia
Biogen

Completed

A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Healthy Volunteer

United States
Biogen

Terminated

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

Parkinson's Disease

Japan
Biogen

Completed

Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease

Healthy Volunteer | Alzheimer's Disease

United States
Biogen

Completed

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

Healthy | Parkinson's Disease

United States
Biogen

Completed

Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants

Healthy Volunteer

United Kingdom
Biogen

Completed

Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.

Healthy Subjects

United States
Biogen

Completed

Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | Healthy Volunteers

United States
Biogen

Terminated

Single Ascending Doses of BIIB063 in Healthy Volunteers

Healthy

United Kingdom
Biogen

Completed

Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes

Multiple Sclerosis | Acute Optic Neuritis

United States

3

Subscribe